FDA Lists Nationwide Recall for Specific Xanax XR Tablets
A nationwide recall now covers one specific batch of Xanax XR, the extended-release version of alprazolam.
Viatris first initiated the recall on March 17, 2026, and the action was expanded nationwide on April 15. The affected medication was distributed across the United States between Aug. 27, 2024, and May 29, 2025.
People reported that this is not a blanket recall for every Xanax product on the market. It involves 3 mg Xanax XR tablets sold in 60-tablet bottles, with lot number 8177156 and an expiration date of February 28, 2027.
Why were the tablets flagged?
According to the California Board of Pharmacy, the reason for the recall is out-of-specification dissolution results. Effectively, the tablets may not dissolve the way they are supposed to, which could affect how the medication releases in the body. The board also said no adverse reactions tied to this lot had been reported as of its notice.
What is Xanax XR?
For some patients, Xanax is part of daily life. MedlinePlus notes that alprazolam, the active ingredient in Xanax, is a benzodiazepine used to treat anxiety disorders and panic disorder.
For Xanax XR specifically, DailyMed says the extended-release tablets are indicated for panic disorder, with or without agoraphobia, in adults.
What should patients check?
On the bottle, the details to look for are include:
- Xanax XR 3 mg
- 60 tablets
- Lot 8177156
- NDC number 58151-506-91
- Expiry of February 2027.
Data from the FDA shows this recall falls under Class II, which means use of the product may cause temporary or medically reversible adverse health consequences, while the chance of serious harm is considered remote.
If those details match what you have at home, stop taking them and dispose of them safely.
More About:Health